133 related articles for article (PubMed ID: 15562199)
1. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.
Wajcberg E; Miyazaki Y; Triplitt C; Cersosimo E; DeFronzo RA
Diabetes Care; 2004 Dec; 27(12):2868-73. PubMed ID: 15562199
[TBL] [Abstract][Full Text] [Related]
2. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
Kipnes M; Dandona P; Tripathy D; Still JG; Kosutic G
Diabetes Care; 2003 Feb; 26(2):421-6. PubMed ID: 12547873
[TBL] [Abstract][Full Text] [Related]
3. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.
Clement S; Still JG; Kosutic G; McAllister RG
Diabetes Technol Ther; 2002; 4(4):459-66. PubMed ID: 12396740
[TBL] [Abstract][Full Text] [Related]
4. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial.
Clement S; Dandona P; Still JG; Kosutic G
Metabolism; 2004 Jan; 53(1):54-8. PubMed ID: 14681842
[TBL] [Abstract][Full Text] [Related]
5. Simulated first-phase insulin release using Humulin or insulin analog HIM2 is associated with prolonged improvement in postprandial glycemia.
DiCostanzo CA; Moore MC; Lautz M; Scott M; Farmer B; Everett CA; Still JG; Higgins A; Cherrington AD
Am J Physiol Endocrinol Metab; 2005 Jul; 289(1):E46-52. PubMed ID: 15713685
[TBL] [Abstract][Full Text] [Related]
6. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.
Halberstam M; Cohen N; Shlimovich P; Rossetti L; Shamoon H
Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019
[TBL] [Abstract][Full Text] [Related]
7. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
Horvath K; Bock G; Regittnig W; Bodenlenz M; Wutte A; Plank J; Magnes C; Sinner F; Fürst-Recktenwald S; Theobald K; Pieber TR
Diabetes Obes Metab; 2008 Jun; 10(6):484-91. PubMed ID: 17764465
[TBL] [Abstract][Full Text] [Related]
8. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
Henry RR; Mudaliar S; Ciaraldi TP; Armstrong DA; Burke P; Pettus J; Garhyan P; Choi SL; Jacober SJ; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen N; Sinha VP; Linnebjerg H
Diabetes Care; 2014 Sep; 37(9):2609-15. PubMed ID: 24947791
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
Leohr J; Dellva MA; LaBell E; Coutant DE; Klein O; Plum-Moerschel L; Zijlstra E; Linnebjerg H
Clin Ther; 2020 Sep; 42(9):1762-1777.e4. PubMed ID: 32900535
[TBL] [Abstract][Full Text] [Related]
10. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
11. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.
Rave KM; Nosek L; de la Peña A; Seger M; Ernest CS; Heinemann L; Batycky RP; Muchmore DB
Diabetes Care; 2005 Oct; 28(10):2400-5. PubMed ID: 16186270
[TBL] [Abstract][Full Text] [Related]
12. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.
Bruttomesso D; Pianta A; Mari A; Valerio A; Marescotti MC; Avogaro A; Tiengo A; Del Prato S
Diabetes; 1999 Jan; 48(1):99-105. PubMed ID: 9892228
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
[TBL] [Abstract][Full Text] [Related]
14. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
15. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
16. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
Ahmed AB; Home PD
Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study.
Iozzo P; Gastaldelli A; Järvisalo MJ; Kiss J; Borra R; Buzzigoli E; Viljanen A; Naum G; Viljanen T; Oikonen V; Knuuti J; Savunen T; Salvadori PA; Ferrannini E; Nuutila P
J Nucl Med; 2006 Jun; 47(6):1016-22. PubMed ID: 16741312
[TBL] [Abstract][Full Text] [Related]
19. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed AB; Mallias J; Home PD
Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
[TBL] [Abstract][Full Text] [Related]
20. Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.
Henriksen JE; Levin K; Thye-Rønn P; Alford F; Hother-Nielsen O; Holst JJ; Beck-Nielsen H
Diabetes; 2000 Jul; 49(7):1209-18. PubMed ID: 10909980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
